Found 1 document(s)
Page 1 of 1
-
Background: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods: We set up an ambispective bicen...